Accelerating Policy Decisions to Adopt Haemophilus influenzae Type b Vaccine: A Global, Multivariable Analysis by Shearer, Jessica C. et al.
Accelerating Policy Decisions to Adopt Haemophilus




¤, Meghan L. Stack
1,2, Marcie R. Richmond
1,2, Allyson P. Bear




1Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America, 2Hib Initiative, Baltimore, Maryland, United States of America
Abstract
Background: Adoption of new and underutilized vaccines by national immunization programs is an essential step towards
reducing child mortality. Policy decisions to adopt new vaccines in high mortality countries often lag behind decisions in
high-income countries. Using the case of Haemophilus influenzae type b (Hib) vaccine, this paper endeavors to explain these
delays through the analysis of country-level economic, epidemiological, programmatic and policy-related factors, as well as
the role of the Global Alliance for Vaccines and Immunisation (GAVI Alliance).
Methods and Findings: Data for 147 countries from 1990 to 2007 were analyzed in accelerated failure time models to
identify factors that are associated with the time to decision to adopt Hib vaccine. In multivariable models that control for
Gross National Income, region, and burden of Hib disease, the receipt of GAVI support speeded the time to decision by a
factor of 0.37 (95% CI 0.18–0.76), or 63%. The presence of two or more neighboring country adopters accelerated decisions
to adopt by a factor of 0.50 (95% CI 0.33–0.75). For each 1% increase in vaccine price, decisions to adopt are delayed by a
factor of 1.02 (95% CI 1.00–1.04). Global recommendations and local studies were not associated with time to decision.
Conclusions: This study substantiates previous findings related to vaccine price and presents new evidence to suggest that
GAVI eligibility is associated with accelerated decisions to adopt Hib vaccine. The influence of neighboring country
decisions was also highly significant, suggesting that approaches to support the adoption of new vaccines should consider
supply- and demand-side factors.
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Routine immunization is an essential component of strategies to
reduce childhood mortality, but its impact is limited by delays in
national decision-making, national and subnational implementa-
tion, and low coverage [1]. While not sufficient, national policy
decisions to adopt vaccines are a necessary condition for their
routine implementation and widespread use.
Haemophilus influenzae type b (Hib) conjugate vaccine prevents
morbidity and mortality resulting from Hib disease, which is
estimated to cause 370,000 deaths each year in unvaccinated
children under five years of age [2]. Where routinely used, Hib
vaccines have reduced morbidity and mortality from Hib disease
[3–7]. Decisions to adopt Hib vaccine in low- and middle-income
countries have lagged behind high-income countries. Its routine
use was confined to 13 low-income countries in 2004; by the end
of 2008, 66 low-income countries had made a decision to adopt
Hib vaccine [8]. In order to explain the increased frequency of
decisions to adopt Hib vaccine since 2004 and to inform efforts
related to other public health interventions, it is useful to
understand what influenced Hib vaccine adoption decisions.
Recent literature has utilized qualitative and quantitative
methods to study decisions to adopt hepatitis B virus (HBV),
Hib, and typhoid vaccines (see Table 1 for a list and description of
studies). Findings from these studies suggest that national vaccine
decision-making is driven by vaccine price [9,10], existence of
local studies or disease burden data [9–14], immunization system
strength [9,13–15], donor financing for vaccines [13–15], and
national economic and political characteristics [15].
The recent increase in decisions to adopt Hib vaccine enables a
longitudinal analysis of previously identified factors, as well as the
addition of variables to test new hypotheses. This paper describes
the results of a multivariable analysis of the factors that may have
shortened the length of time between vaccine availability and a
country’s decision to adopt Hib vaccine. As new vaccines and
other public health technologies become available, a better
understanding of the factors that are associated with accelerated
adoption of appropriate technologies could speed health improve-
ments for populations around the world.
Methods
The study outcome is a policy decision of a country to
universally adopt Hib vaccine. Compared with programmatic
implementation, which can vary subnationally, policy decisions
correspond to a discrete time point at the national level. For
Global Alliance for Vaccines and Immunisation (GAVI)-eligible
countries, decision year is defined as the year that a country
applied to GAVI for new vaccine financial support. GAVI
Alliance, a global public-private partnership, was created in
2000 to improve access to underutilized vaccines, including Hib
vaccine (see Box 1). For non-GAVI–eligible countries, we use the
year that Hib vaccine first appeared in the country’s immunization
schedule, as dates of policy decisions were not available [16].
Because a decision can occur only once, countries are censored
from the model the year following a decision.
Countries entered the model when a Hib-containing conjugate
vaccine was first available for use in their country. This
corresponded to the year of Hib conjugate licensure (1990) for
most high- and middle-income countries, and the year of WHO
prequalification (1998) for countries that procure vaccines through
UNICEF. Of 193 countries reporting data to WHO and World
Bank, 19 were excluded from the model because of missing
explanatory data .10%.
Explanatory variables were proposed on the basis of existing
literature. A core model included four explanatory variables.
Additional variables were chosen to further describe contextual
factors, the costs and benefits of introducing Hib vaccine, and
factors that modify decision-makers’ perception of these costs and
benefits (Table S1). Fourteen variables were included in the final
model according to these categories and the constraints of the
statistical model (Table 2). These variables and our hypotheses of
their effects are described below.
Variables to describe the underlying country context are
geopolitical region, coverage of three doses of diphtheria, tetanus,
and pertussis vaccine (DTP3) [17], and democracy score [18]. The
model controls for population size [17]. DTP3 coverage is used as
a proxy for immunization system strength, and we expect a
positive association between DTP3 and accelerated decision-
making. Level of democracy was captured using an existing
continuous scale (democracy score) that quantifies type of
governance, ranging from fully institutionalized autocracy (210)
to fully institutionalized democracy (+10) [18]. We expect that
decision-making was accelerated in more democratic states [15].
Costs and benefits of Hib vaccine introduction were measured
by vaccine price per dose, cost per bed-day (International $; Int$)
[19], Hib disease incidence [2], and the availability of Hib-
containing combination vaccines (DTP-HBV-Hib and DTP-Hib).
This latter construct was represented by a dummy variable for
years 2002–2007. The model controls for gross national income
(Atlas US$; abbreviated as GNI) [17]. Vaccine price per dose was
collected from public sources [20–24], published economic
analyses [25–27], and personal communication with country
governments. For GAVI-eligible countries, we used the subsidized
price that they would pay after GAVI’s cofinancing contribution.
For non-GAVI–eligible countries where data were unavailable,
the median price for that country’s income strata was used. To
reflect historical changes in price for countries paying a private
market price (i.e., not UNICEF or GAVI pricing), we applied the
trajectory of the historical price trend paid by the US government
[23]. We expect an association between decreases in vaccine price
and accelerated decision-making [9,10]. Cost per bed-day [19]
was converted to year-specific costs using GDP deflators and
purchasing power parity data available from the World Bank
World Development Indicator database [17]. Estimates of
country-level Hib disease incidence were obtained from the Hib
and Pneumococcal Global Burden of Disease Study [2]. While
high disease incidence should encourage policy action, low
national income in high-burden countries suggests that the
perceived costs of vaccination may have outweighed the perceived
benefits in these settings. We expect that Hib vaccine will be more
attractive to decision-makers in combination with other antigens
and will be associated with accelerated decision-making.
To measure factors that could modify a decision-maker’s
perception of the costs and benefits of Hib vaccine and its position
on the policy agenda, we include variables to describe the
existence of local Hib studies, decisions of neighboring countries,
WHO recommendations [3,28], GAVI eligibility [29], and
cofinancing uncertainty. The number of high-quality published
local studies is measured by a continuous variable and based on a
bibliography of Hib disease burden studies [30]. We hypothesize
that local studies would have increased general awareness of Hib
disease amongst decision-makers, thus accelerating time to
decision [10–13,31]. Number of neighboring adopters was
determined by mapping vaccine introduction for each year. A
country was defined as having ‘‘N’’ neighboring adopters if ‘‘N’’
countries sharing an international border had already adopted Hib
vaccine. Island countries were considered to share a border with
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sion-makers have indicated through interviews that neighboring
countries’ actions influence their own decisions [10,13,32] and we
expect to find the same.
The WHO has published two recommendations regarding Hib
vaccine. The 1998 position paper states that countries should
consider Hib burden before introducing the vaccine [28]; a 2006
modification recommends the inclusion of Hib vaccine in all
routine immunization programs, regardless of national burden [3].
Both position papers are represented by separate dummy variables
for their respective years, and we anticipate that they accelerated
time to decision.
Since 2000, countries with GNI per capita less than $1,000
(2003 US$) have been eligible to apply for support from GAVI
(Box 1) [29]. GAVI eligibility is a time-varying binary variable.
Whether or not a country applies for or receives support, they are
Table 1. Previous findings on factors that influence national vaccine decision-making.
Author Important Variables Methods Vaccine
Widdus (1999) [31] N Local burden of disease and vaccine
effectiveness studies
N Cost-effectiveness studies
N Cost reduction and knowledge sharing
platforms for poorer countries
N International recommendations
N Private sector use
N Social/behavioral research to understand
local barriers to acceptance
N Advocacy for economic benefit of vaccine
N Emerging market technology licensing
N Coordinating approval process of vaccines in
all countries
N Donor financing
Conceptual framework of suggested




Wenger et al. (2000) [11] N Published burden of disease and effectiveness
studies
N Local experience with vaccine
N Support from pediatrician association
N Price
N Public interest (political will)
N Surveillance data
Case study of four early adopting,
nonindustrialized countries
Hib
Miller and Flanders (2000) [9] N DTP3 coverage
N GDP per capita
N Vaccine cost (price per dose)
N Treatment cost per unit
N Years of life lost
N Years of life lost
N Treatment cost prevented
N Years of life saved




N GDP per capita
N DTP3 coverage
N Presence of UNICEF financing
N PAHO revolving fund membership
N Institutional quality score
Longitudinal multivariable analysis HBV
DeRoeck et al. (2005) [12] N Burden of disease studies
N Cost-effectiveness studies
N Vaccine price
N Vaccine safety and immunogenicity
N Feasibility of local production
N WHO recommendation








Munira and Fritzen (2007) [13] N External pressures and advocacy
N Burden of disease studies
N Scientific support on benefit of vaccine
N Feasibility of adoption into current EPI
N Local vaccine pilot studies
Case studies of two early adopting
countries (Taiwan, Thailand)
HBV
Rossi et al. (2007) [14] N Geographical region
N DTP3 coverage
N Previous introduction of HBV
N GNI per capita




N Burden of disease and impact studies
N ‘‘Experience exchange’’ between countries
N PAHO Revolving Fund membership
Descriptive analysis and case
studies from the Americas
Hib
Studies were identified by searching for keyword combinations of ‘‘Hib,’’ ‘‘new vaccine,’’ or ‘‘immunization’’ and ‘‘policy,’’ ‘‘adoption,’’ or ‘‘government factors’’ in
PubMed, SCOPUS, PAIS International, EconLit, and WorldCat. Additional articles were identified by reviewing references of retrieved studies.
doi:10.1371/journal.pmed.1000249.t001
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in years 2000–2007 and zero (non-GAVI–eligible) if they do not
meet eligibility criteria; all countries are coded as zero in years
before 2000. Because the final model includes a variable for price
per dose, the GAVI variable represents GAVI-funded advocacy
and technical support external to actual financial disbursements
for new vaccines. We hypothesize that being GAVI-eligible
modified decision-makers’ awareness of Hib vaccination and
elevated its position on the policy agenda. The cofinancing
uncertainty variable accounts for a period of time (2004–2006)
when GAVI was in the process of revising its financing policy. This
dummy variable flags observations for GAVI-eligible countries
from 2004 to 2006 to explore the relationship between price
uncertainty and the lower incidence of decisions to introduce
during those years.
Survival analysis was used to model how time-varying factors
affect the duration of time between vaccine availability and a
country’s policy decision to adopt. Survival functions and their
differences are described by Kaplan-Meier curves and by log-rank
tests, respectively. For multivariable analyses, we used an
accelerated failure time (AFT) model in preference to a
semiparametric proportional hazard model, as AFT models are
more robust to the presence of unobservable confounders for each
country. However, they require parametric assumptions regarding
both the distribution of the time to event and the distribution of
the frailty parameter [33]. Our study explored the robustness of
the results of a basic set of variables to the Weibull [34], log-
normal and log-logistic distributions and to both gamma and
Gaussian frailty assumptions. Choice of model did not significantly
alter the regression coefficients or results of the log-likelihood test
(Table S2); however, a Weibull distribution with Gaussian frailty
was chosen as the best fit. Variables were added to a core model
using manual forward stepwise selection that considered theoret-
ical hypotheses. The final model of 14 independent variables was
selected based on the results of likelihood ratio and Akaike
information criteria [35]. Sensitivity analysis measured possible
overadjustment for income by rerunning the model without GNI.
Analysis was performed with Stata statistical software version 10.0
(College Station, TX).
Results
One hundred and forty-seven countries were amenable to
analysis in the final AFT model, accounting for 1,383 country-
years of observation between 1990 and 2007. By 2007, 39
countries had not yet made a policy decision to adopt Hib vaccine
and were right censored, which was taken into consideration by
the likelihood model [36]. The Kaplan-Meier survival curves
depict the time from licensure (availability) of vaccine to decision.
While the GAVI and non-GAVI curves follow similar trajectories
for the first nine years, the significant acceleration observed for
GAVI-eligible countries in year 10 (2007; see Figure 1) results in a
statistically significant difference between the curves overall (log
rank test p=0.002). In Figure 2, GAVI eligibility appears to
correct for differences between income levels (p,0.001 comparing
low-income countries (LIC) with lower-middle income countries
(LMC); p=0.04 comparing LIC with upper-middle income
countries (UMC)). Figure 3 demonstrates the effect of neighboring
countries’ decisions: bordering two or more adopters accelerates
decision-making (log rank test p,0.001). This effect held for both
GAVI-eligible and non-GAVI–eligible countries.
In the multivariable AFT model, the effects of individual
variables on time to decision were measured while controlling for
all other modeled variables (see Table 3). The exponentiated
coefficients in Table 3 describe the factor by which the expected
time to decision is multiplied for each unit increase in the
independent variable, all other variables held constant. Coeffi-
cients less than one indicate accelerated time to decision.
In the multivariable AFT model, non-OECD (Organisation for
Economic Co-operation and Development) European and Central
Asian countries’ time to decision was lengthened by a factor of
more than three (95% CI 1.67–6.66) as compared to the high-
income OECD reference group. Countries in the East Asia and
Pacific region experienced a delay of over two times (95% CI
1.02–5.95). DTP3 coverage was not statistically significantly
associated with time to decision, but each increase in degree of
democracy – for example, the difference between Argentina in
1991 and in 1999 [18]—shortened time to decision by a factors of
0.97 (95% CI 0.94–0.999).
Each 1% increase in price per dose was associated with a 1.02
times longer time to decision (95% CI 1.00–1.04), controlling for
national income. Neither cost per bed-day, incidence of Hib
disease, nor availability of Hib in a combination vaccine were
statistically significant.
The existence of local studies was not statistically significantly
related to a change in time to decision. However, decision-
making was accelerated by decisions to adopt Hib vaccine in
neighboring countries. Bordering one neighboring decider
shortened the time to adoption by a factor of 0.67 (95% CI
0.48–0.94) while two or more neighboring deciders shortened the
time to adoption by 0.50 (95% CI 0.33–0.75). Neither of the
WHO position statements was statistically significantly associated
with time to decision.
Box 1. GAVI Background
GAVI offers financial, technical, and health systems support
to national immunization programs in the world’s 72
poorest countries (GNI per capita less than $1,000; 2003
USD). These 72 countries are all considered GAVI-eligible,
but to apply for support, countries must also have a
functional interagency coordinating committee and DTP3
coverage .50%.
Available support
Eligible countries can apply to GAVI for:
N Cofinancing support for new and underused vaccines
(HBV, Hib, yellow fever, pneumococcal, rotavirus, mea-
sles)
N Immunization services support (flexible funding to
improve immunization performance)
N Injection safety support
N Health systems strengthening (flexible funding to target
health systems constraints)
N Civil society organization support
In addition to offering these forms of ‘‘hard’’ support, GAVI
also engages in global advocacy, liaises with national
decision-makers and stakeholders, and funds vaccine-
specific initiatives such as the Hib Initiative.
Funding received
As of July 2009, 71 countries had submitted successful
applications for various forms of GAVI support, including
cofinancing for new and underused vaccines (n=49); health
systems strengthening (n=28); immunization services
support (n=61); and injection safety support (n=66).
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0.37 (95% CI 0.18–0.76) holding vaccine price and all other covariates
constant. Exposure to the period of uncertain financing (2004–2006)
mediated GAVI’s effect, shortening time to decision by 0.83 (the GAVI
coefficient multiplied by the cofinancing uncertainty coefficient). The
final model was minimally sensitive to GNI; removing GNI reduced
the GAVI coefficient by three percentage points.
Discussion
Consistent with our hypotheses, adoption time was associated
with the costs and benefits of Hib immunization, and by factors
that might influence decision-makers’ perceptions of these costs
and benefits. Notably, being GAVI-eligible was associated with a
significant accelerating effect on time to decision. The principal
mechanisms through which GAVI could hasten adoption
decisions, independent of financing, likely include advocacy
efforts, interpersonal contact with national decision-makers, and
technical support. The high degree of correlation of these efforts
across GAVI countries does not permit efforts to disentangle them.
The creation of the GAVI-funded Hib Initiative in 2005 may
explain the surge of decisions in GAVI-eligible countries in 2007
(see Figure 1, year 10), but too few country-years exist to confirm
or refute this hypothesis.
The presence of two or more neighboring adopters accelerated
time to decision by a factor of 0.50, suggesting a process of policy
diffusion as has been indicated through qualitative research
[10,13,32]. In this model, WHO recommendations did not
accelerate time to decision. Rather than minimizing the saliency
of such recommendations, the aggregate of the findings suggests
that their influence could be strengthened through dissemination
via regional networks.
Previous research has described the influence of local evidence
on decision-making [9–14], a finding that was not substantiated
here. However, we were not able to model the results of local
studies, only their existence. Knowing that studies exist is not
equivalent to knowing the implications of their findings or their
dissemination to decision-makers. At the same time, the influence
of local studies is not necessarily proportional to their quality or
validity. Limited data and poor model fit prevented attempts to
model the actual findings of local incidence studies, and the local
incidence estimates from the Global Burden of Disease study were
nonsignificant, perhaps due to regional heteroskedasticity gener-
ated by their modeling process.
Table 2. Summary statistics of included independent variables.
Variables Type Median (Lower; Upper Quartile) or N (%)
a
Context
Natural log population (1,000s) Continuous 15.67 (14.16; 17.96)
Region: High-income OECD Binary 137 (7.95)
East Asia and Pacific Binary 209 (12.12)
Europe and Central Asia Binary 282 (16.36)
Latin America and Caribbean Binary 291 (16.88)
Middle East and North Africa Binary 149 (8.64)
Other high-income Binary 153 (8.87)
South Asia Binary 60 (3.48)
Sub-Saharan Africa Binary 443 (25.7)
DTP3 coverage (%) Continuous 88 (75; 96)
Democracy score Continuous 5 (24; 8)
Costs and benefits
Natural log price per dose (US$) Continuous 1.26 (21.17; 1.51)
Natural log GNI (US$) Continuous 22.80 (21.43; 24.58)
Natural log cost per bed-day (Int$) Continuous 4.02 (3.39; 4.54)
Incidence of Hib disease (per 100,000 child-years) Continuous 820 (450; 1562)
Availability of Hib in combination with DTP and/or HBV Binary 304 (17.60)
Modifying factors
Local incidence/disease burden studies Continuous 0 (0; 0)
Neighboring adopters: None Binary 1,130 (65.55)
One neighboring country adopter Binary 331 (19.2)
Two or more neighboring country adopters Binary 263 (15.26)
WHO position paper: None Binary 688 (39.91)
First WHO position Binary 890 (51.62)
Second WHO position Binary 146 (8.47)
GAVI eligibility Binary 432 (25.1)
Cofinancing uncertainty Binary 148 (8.58)
aN=country-years.
doi:10.1371/journal.pmed.1000249.t002
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model found no association between immunization system
strength, as measured by DTP3 coverage, and time to decision
to introduce the Hib vaccine. Considering the potential for
collinearity between DTP3 coverage and national income, it is
conceivable that the surge of decisions in low-income countries
masks any potential effect of DTP3.
Strengths and Weaknesses of the Study
To our knowledge, this study is the first to use longitudinal,
multivariable methods to describe Hib vaccine policy decisions, and
to incorporate the influence of GAVI and neighboring countries. Our
model is explanatory rather than predictive, thus its findings cannot
be directlyapplied to newer vaccines. Nor couldour modelinclude all
possible covariates or countries; 19 countries were excluded due to
Figure 1. Time to decision by GAVI and non-GAVI countries. Time=0 represents first availability (licensure) of Hib vaccine (1998 for UNICEF
procurers; 1990 for others).
doi:10.1371/journal.pmed.1000249.g001
Figure 2. Time to decision by World Bank income group. See [17].
doi:10.1371/journal.pmed.1000249.g002
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were earlier deciders (p=0.008), had smaller populations (p,0.001),
and were less democratic (p,0.001) than the included countries.
Findings from this analysis may not be generalizable to the excluded
countries. Covariates were excluded because of model constraints,
missing data, and difficulties in operationalizing certain theoretical
constructs, including those related to political and historical influence,
institutions, actors, and advocacy.
Finally, the choice of entry time into our model artificially
underestimates the true delay in access for most low- and middle-
income countries. We consider these countries to enter at the time
of WHO licensure (1998), which was eight years after the vaccine’s
US licensure. This eight-year delay is related to issues of supply
and cost. The choice of entry time, while reflective of available
policy options in developing countries, may bias results towards
faster adoption in GAVI-eligible countries.
Implications
Although limited to explaining decision patterns of Hib vaccine,
these findings may be of interest to other public health programs with
similar goals. For example, they highlight the potential of formal and
informal networks to facilitate policy diffusion, including regional
organizations (e.g., PAHO), regional forums and meetings (e.g.,
WHO Expanded Programme on Immunization [EPI] manager
meetings), and new-vaccine application workshops. Recent global
interest in facilitating South-South learning and cooperation should
be encouraged and explored further.
Vaccine price remains a significant barrier for many middle-
income countries, but the expansion of bulk purchasing models
similar to the PAHO revolving fund or the Gulf Cooperation
Council group purchasing model offers promise of secure and
affordable supply [37]. However, findings from our model
substantiate historical evidence that suggests that price alone will
not drive decision-making. At GAVI’s inception, countries could
obtain Hib vaccine for free, yet the rate of adoption decisions
increased only after a cofinancing requirement was enacted (year 10
in Figure 1). In fact, the effect of price uncertainty during GAVI’s
period of policy transition (2004–2006) was larger than the effect of
the vaccine price itself. These findings suggest that long-term price
and supply certainty should be prioritized for other new vaccines.
This study demonstrates the importance of both supply- and
demand-side approaches in accelerating decisions to adopt cost-
effective, underutilized public health technologies. In the cases of
human papillomavirus, pneumococcal, and rotavirus vaccines,
GAVI’s new Accelerated Vaccine Introduction initiative may wish
to consider additional factors unique to these newer vaccines.
Further Research
Further research should attempt to operationalize additional
theoretical constructs of policy decision-making and measure them
prospectively. Measuring the level and intensity of various GAVI
activities could better elucidate mechanisms through which GAVI
might accelerate decision-making. Measurement of domestic
decision-making processes, including the influence of national
immunization technical advisory committees, would be an
important contribution.
Future research should explore the effect of neighboring
countries’ research evidence, including disease burden and vaccine
impact studies. As policy decisions are implemented, future
analyses should measure time to implementation. In addition,
evaluation of programmatic outcomes, including coverage and
lives saved, will inform discussions related to timely access and
programmatic effectiveness.
Progress toward meeting national and global health and
development targets depends on appropriate national policies.
We hope that these findings inform efforts to support evidence-
based policy decisions to adopt proven, cost-effective public health
interventions.
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Background. Every year, immunization averts more than 2
million deaths by preparing people’s immune systems to
recognize and attack disease-causing organisms (pathogens)
rapidly and effectively. Although the immune system is
designed to protect the human body against infections, the
first time a person is exposed to a pathogen (usually during
early childhood) their immune system can take some time to
respond. As a result, they can become seriously ill or even
die. However, the immune system ‘‘learns’’ from the
experience and when the pathogen is encountered again,
the immune system swings into action much more quickly.
Immunization or vaccination is a safe way to make
individuals resistant to infectious diseases. It works by
exposing them to weakened or dead pathogens or to
pathogen molecules (antigens) that the immune system
recognizes as foreign. Widespread, routine immunization of
children is, therefore, an essential component of national
and global strategies to reduce childhood illnesses and
deaths.
Why Was This Study Done? Although many factors affect
the uptake of immunization (in particular, vaccine prices),
national policy decisions to adopt new vaccines are an
essential step toward improving coverage. Unfortunately,
these decisions are often delayed in developing countries.
Thus, although many industrialized countries have routinely
immunized their children with the highly effective
Haemophilus influenza type b (Hib) conjugate vaccine since
it became available in the early 1990s, only 13 low-income
countries were using the vaccine in 2004. Hib bacteria, which
cause pneumonia (lung infection) and meningitis (brain
inflammation), kill about 370,000 unvaccinated young
children every year. In this study, the researchers try to
explain delays in the adoption of routine Hib vaccination in
developing countries by analyzing the associations between
Hib vaccination and factors such as national economic
status, local Hib burden, and eligibility for support from the
Global Alliance for Vaccines and Immunisation (GAVI
Alliance; a public–private partnership that offers financial,
technical, and health systems support for the introduction of
national immunization programs to developing countries
that meet certain eligibility criteria).
What Did the Researchers Do and Find? The researchers
used a statistical approach called accelerated failure time
analysis to analyze data collected in 147 countries between
1990 and 2007 on vaccine costs, Hib disease incidence, GAVI
eligibility, and other factors that could influence decision-
makers’ perceptions of the costs and benefits of Hib
vaccination. After allowing for gross national income,
region, and burden of Hib disease, the researchers
identified several factors that influenced the time between
the availability of a Hib conjugate vaccine in a country and a
decision being made to introduce routine Hib vaccination.
The receipt of GAVI support speeded the decision to adopt
vaccination by 63%, for example, and sharing borders with
two or more countries that had adopted the vaccine
speeded the decision by 50%. By contrast, for each 1%
increase in vaccine costs, the time to decision to adopt
vaccination was delayed by 2%. The 1998 and 2006 World
Health Organization recommendations on routine Hib
vaccination and the existence of local studies on Hib
disease had no influence on the time to decision.
What Do These Findings Mean? These findings confirm
previous studies that showed that increases in the price of
Hib vaccine increase the time to adoption. In addition, they
suggest that GAVI eligibility accelerates decisions to adopt
this vaccine and show that the decisions made by
neighboring countries are important, which suggests that
policy diffusion may occur. Thus, in the case of adoption of
the Hib vaccine, both supply-side and demand-side factors
seem to be important. Its is relevant to note that during
writing of the article, JCS, MLS, MRR, APB, and RAH were
employed by the Hib Initiative, which was funded by the
GAVI Alliance. The findings do not necessarily represent the
views, policies or decisions of the Hib Initiative or the GAVI
Alliance. Importantly, these findings are explanatory, not
predictive, so they cannot be applied directly to new
vaccines to improve their rate of adoption. Nevertheless,
these findings highlight the potential importance of setting
up formal and informal networks to facilitate policy diffusion
and suggest that long-term price and supply certainty might
be factors that could help to accelerate national decisions to
adopt new and/or underutilized vaccines and other public-
health technologies.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000249.
N The World Health Organization provides information on
immunization and on Haemophilus influenza type b (in
several languages)
N The GAVI Alliance Web site describes the work of this
public–private partnership and provides details of devel-
oping countries eligible for Hib vaccination support
N The Hib Initiative aims to reduce the risk of childhood
death and disability through sustained use of Hib vaccine
N MedlinePlus provides links to further resources on
immunization and information on the Haemophilus influ-
enzae type b vaccine (in English and Spanish)
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